Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Disrupted synaptic vacuolar H+-ATPase renders synaptic vulnerability to Alzheimer’s disease
Yanting Chen, Khloud Ashraf Farouk Emam, Shuwen Yue, Jing Tian, Tienju Wang, Albert Park, Shalini Mishra, Gagan Deep, Zi-Jun Wang, Heng Du, Lan Guo
Yanting Chen, Khloud Ashraf Farouk Emam, Shuwen Yue, Jing Tian, Tienju Wang, Albert Park, Shalini Mishra, Gagan Deep, Zi-Jun Wang, Heng Du, Lan Guo
View: Text | PDF
Research Article Aging Neuroscience

Disrupted synaptic vacuolar H+-ATPase renders synaptic vulnerability to Alzheimer’s disease

  • Text
  • PDF
Abstract

Defective synaptic transmission is a prominent pathology that underlies cognitive deficits in Alzheimer’s disease (AD), highlighting the need to elucidate molecular mechanisms of synaptic failure. Vacuolar H+-ATPase (V-ATPase), a proton-pumping enzyme, is essential for synaptic vesicle acidification and neurotransmitter loading. However, whether SV-associated V-ATPase is vulnerable to AD remains unclear. Here, using SV-rich fractions from postmortem brain tissues, we identified SV-associated V-ATPase deficits, including decreased enzymatic activity, impaired complex assembly, and altered expression of its key subunits in AD. SV-associated V-ATPase dysfunction was further associated with pathological and clinical characteristics of AD. Genetic downregulation of the V-ATPase V1D subunit, a component reduced in AD brains, disrupted V-ATPase proton transport and impaired SV acidification. Further experiments using 5×FAD mice, which exhibited AD-like SV-associated V-ATPase deficits, demonstrated the deleterious impact of V-ATPase dysfunction on SV acidification and synaptic transmission including presynaptic neurotransmitter release. In addition, ex vivo studies identified amyloid β–induced oxidative stress as a driver of V1D loss and V-ATPase disassembly, linking AD pathology to SV-associated V-ATPase dysfunction. These findings indicate that SV-associated V-ATPase dysfunction contributes to synaptic failure and cognitive deficits in AD. Therapeutic avenues to mitigate V-ATPase dysfunction have the potential to attenuate synaptic failure for the management of AD.

Authors

Yanting Chen, Khloud Ashraf Farouk Emam, Shuwen Yue, Jing Tian, Tienju Wang, Albert Park, Shalini Mishra, Gagan Deep, Zi-Jun Wang, Heng Du, Lan Guo

×

Figure 1

V-ATPase dysfunction in SV-rich fractions from patients with AD.

Options: View larger image (or click on image) Download as PowerPoint
V-ATPase dysfunction in SV-rich fractions from patients with AD.
(A) Mea...
(A) Measurement of V-ATPase ATP hydrolysis capacity in SV-rich fractions: 200 nM concanamycin was used as a selective V-ATPase inhibitor to determine the concanamycin-sensitive V-ATPase activity. Unpaired 2-tailed t test. n = 7 per group in controls without AD and patients with AD. (B and C) BN-PAGE and immunoblotting to examine V-ATPase fully assembled complexes and assembly intermediates based on detection of V0c subunit. (B) Representative immunoblot images. (C) Quantification of the proportion of the fully assembled complex and assembly intermediates. The fully assembled complex and intermediate 1 were analyzed using the Mann-Whitney U test; intermediate 2 was analyzed using an unpaired 2-tailed t test. Controls without AD: n = 6; patients with AD: n = 7. (D and E) Immunoblot analysis of key subunits of the V-ATPase complexes in SV-rich fractions. (D) Representative immunoblot images. (E) Quantification of the expression level of key V-ATPase subunits. Synaptophysin was used as a loading control. The expression levels of V-ATPase subunits in patients with AD were normalized to those in controls without AD. Unpaired 2-tailed t test, controls without AD, n = 6; patients with AD, n = 6.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts